Longitudinal Evaluation of Compressor/Nebulizer Performance

References

1. 1.↵
   1. O'Sullivan BP,
   2. Freedman SD

   . Cystic fibrosis. Lancet 2009;373(9678):1891–1904.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   Cystic Fibrosis Foundation Patient Registry. Annual data report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2010.
3. 3.↵
   1. Ratjen FA

   . Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009;54(5):595–605.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Flume PA,
   2. O'Sullivan BP,
   3. Robinson KA,
   4. Goss CH,
   5. Mogayzel PJ Jr.,
   6. Willey-Courand DB,
   7. et al

   . Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176(10):957–969.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Mogayzel PJ Jr..,
   2. Naureckas ET,
   3. Robinson KA,
   4. Mueller G,
   5. Hadjiliadis D,
   6. Hoag JB,
   7. et al

   . Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680–689.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   Tobi [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2009.
7. 7.↵
   1. Heijerman H,
   2. Westerman E,
   3. Conway S,
   4. Touw D,
   5. Döring G

   ; consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8(5):295–315.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Fuchs HJ,
   2. Borowitz DS,
   3. Christiansen DH,
   4. Morris EM,
   5. Nash ML,
   6. Ramsey BW,
   7. et al

   . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331(10):637–642.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Scherer T,
   2. Geller DE,
   3. Owyang L,
   4. Tservesta M,
   5. Keller M,
   6. Boden N,
   7. et al

   . A technical feasibility study of dornase alfa delivery with eFlow vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci 2011;100(1):98–109.

   OpenUrlPubMed
10. 10.↵
    Pulmozyme [package insert]. Genentech, South San Francisco, CA; 2010.
11. 11.↵
    1. Donaldson SH,
    2. Bennett WD,
    3. Zeman KL,
    4. Knowles MR,
    5. Tarran R,
    6. Boucher RC

    . Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354(3):241–250.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Dolovich MB,
    2. Dhand R

    . Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377(9770):1032–1045.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Le Brun PP,
    2. de Boer AH,
    3. Heijerman HG,
    4. Frijlink HW

    . A review of the technical aspects of drug nebulization. Pharm World Sci 2000;22(3):75–81.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Bauer A,
    2. McGlynn P,
    3. Bovet LL,
    4. Mims PL,
    5. Curry LA,
    6. Hanrahan JP

    . Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution. Respir Care 2009;54(10):1342–1347.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Hess D,
    2. Fisher D,
    3. Williams P,
    4. Pooler S,
    5. Kacmarek RM

    . Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110(2):498–505.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Smith EC,
    2. Denyer J,
    3. Kendrick AH

    . Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995;89(3):157–159.

    OpenUrl
17. 17.↵
    1. Standaert TA,
    2. Bohn SE,
    3. Aitken ML,
    4. Ramsey B

    . The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 2001;14(1):31–42.

    OpenUrlPubMed
18. 18.
    1. Standaert TA,
    2. Vandevanter D,
    3. Ramsey BW,
    4. Vasiljev M,
    5. Nardella P,
    6. Gmur D,
    7. et al

    . The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000;13(2):147–153.

    OpenUrlPubMed
19. 19.↵
    1. Reisner C,
    2. Katial RK,
    3. Bartelson BB,
    4. Buchmeir A,
    5. Rosenwasser LJ,
    6. Nelson HS

    . Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001;86(5):566–574.

    OpenUrlPubMedWeb of Science
20. 20.↵
    1. de Boer AH,
    2. Hagedoorn P,
    3. Frijlink HW

    . The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser. Int J Pharm 268(1–2):59–69, 2003.

    OpenUrlPubMed
21. 21.↵
    1. Standaert TA,
    2. Morlin GL,
    3. Williams-Warren J,
    4. Joy P,
    5. Pepe MS,
    6. Weber A,
    7. Ramsey BW

    . Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 1998;114(2):577–586.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Berlinski A,
    2. Hayden JB

    . Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv 2010;23(6):397–404.

    OpenUrlPubMed
23. 23.↵
    1. Bauer A,
    2. McGlynn P,
    3. Bovet LL,
    4. Mims PL,
    5. Curry LA,
    6. Hanrahan JP

    . The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care 2009;54(11):1488–1492.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Chavez A,
    2. McCracken A,
    3. Berlinski A

    . Effect of face mask static dead volume, respiratory rate and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol 2010;45(3):224–229.

    OpenUrlPubMed
25. 25.↵
    1. Barry PW,
    2. O'Callaghan C

    . Drug output from nebulizers is dependent on the method of measurement. Eur Respir J 1998;12(2):463–466.

    OpenUrlAbstract